Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $15.61, but opened at $16.15. Telix Pharmaceuticals Limited American Depositary Shares shares last traded at $15.70, with a volume of 738 shares trading hands.
Analysts Set New Price Targets
Several research analysts recently commented on TLX shares. William Blair raised Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a research report on Tuesday, November 19th. UBS Group started coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report on Friday, November 15th. They set a “buy” rating and a $21.00 target price on the stock.
View Our Latest Analysis on TLX
Telix Pharmaceuticals Limited American Depositary Shares Price Performance
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
Featured Articles
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Stock Dividend Cuts Happen Are You Ready?
- Micron Technology: Riding the AI Wave to Long-Term Growth
- Transportation Stocks Investing
- 3 Cheap Small-Cap Banks for Dividend Growth Investors
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.